Devgen NV Completes the Final Closure of its Pharma Division, Lays off 19 Employees

Devgen (Euronext Brussels: DEVG) has reached a collective labor agreement following negotiations with the social partners. This agreement is a result of the previously announced intention to close Devgen's pharma division. This closure will lead to the employment of the 19 employees, active in this division, to be terminated effective December 31, 2008.

About Devgen

Devgen is a public agricultural biotech and seed company focused on developing and commercializing:

• biotech traits and hybrid seeds to meet the growing needs for high yielding, high quality hybrid rice, sorghum, millet and sunflower of the Indian and other South-East Asian markets;
• a novel generation of biotech products to protect a wide spectrum of crops incurred from pests; to render crops more tolerant against stress factors such as drought and salty soils and to decrease the need for fertilizer use by optimizing nitrogen uptake;
• a new generation of agrochemical products to protect crops from damage inflicted by plant parasitic nematodes.

Incorporated in 1997, Devgen has offices in Ghent (Belgium), Singapore, Hyderabad (India) and Delaware (US) and employs more than 200 people worldwide. Devgen is listed on Euronext Brussels (ticker: DEVG) since June 2005.

For more information please contact:

Thierry Bogaert, CEO Wim Goemaere, CFO Tel. +32 9 324.24.24 Tel. +32 9324.24.24 Thierry.Bogaert@devgen.com Wim.Goemaere@devgen.com

or visit: www.devgen.com